Company intelligence / Profile preview

UNIKUM Therapeutics

Copenhagen, Denmarkinternational.au.dk ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

UNIKUM Therapeutics has developed methods to genetically engineer plasmacytoid Dendritic Cells (pDCs), enhancing their therapeutic potential for cancer immunotherapy. Their lead candidate pDC-STINGGoF is in preclinical development for solid tumors[2].

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyHematopoietic stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

PIRC100

Pre-clinical

Indications: Cancer

Beyond the preview

Go deeper on UNIKUM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNIKUM Therapeutics.

Explore the full profile